

MAY 05 2003

PATENT & TRADEMARK OFFICE

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

| | |
|------------------------|---------------------|
| Application Number | 10/057,339 |
| Filing Date | 01/25/2002 |
| First Named Inventor | T. Kosoglou, et al. |
| Art Unit | 1614 |
| Examiner Name | To Be Assigned |
| Attorney Docket Number | CV01490K |

Total Number of Pages in This Submission

5

RECEIVED


MAY 07 2003

TECH CENTER 1600/2900

ENCLOSURES (Check all that apply)


- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Terminal Disclaimer | <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Request for Refund | Form PTO-1449 (1 pg. in dup.); |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> CD, Number of CD(s) _____ | References (13); Post Card |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> Remarks _____ | |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|--------------------|---|
| Firm or Individual | Ann Marie Cannoni, Reg. No. 35,972 |
| Signature |  |
| Date | April 28, 2003 |


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: April 28, 2003

| | | | |
|------------------|---|------|----------------|
| Typed or printed | Ann Marie Cannoni | | |
| Signature |  | Date | April 28, 2003 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT CASE CV01490K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10
LB
5/9/03

-----X
In re Application of:
T. Kosoglou, et al.

: Examiner: To Be Assigned

For:
**COMBINATIONS OF STEROL
ABSORPTION INHIBITOR(S) WITH
CARDIOVASCULAR AGENT(S) FOR THE
TREATMENT OF VASCULAR CONDITIONS:**

: Group Art Unit: 1614

: Attorney Docket No.: CV01490K

Serial No.: 10/057,339

Filed: **January 25, 2002**
-----X

Assistant Commissioner of Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

MAY 07 2003

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants respectfully request that the following be considered and made of record, as well as the documents listed on the accompanying PTO Form 1449.

A research study was initiated on April 17, 1997 in the United States in which patients were administered capsules of the formulations of Exhibits A, B or C. Copies of the formulation Exhibits A, B and C and the informed consent form for the study (Exhibit 1) are submitted herewith for the Examiner's consideration.

A research study was initiated on October 21, 1997 in the United States in which patients were administered tablets of the formulations of Exhibits D or E or capsules of formulation of Exhibit C. Copies of the formulation Exhibits C, D and E and the informed consent for the study (Exhibit 2) are submitted herewith for the Examiner's consideration.

A research study was initiated on November 5, 1998 in the United States in which patients were administered tablets of formulations of Exhibits D, F, G or H. Copies of the formulation Exhibits D, F, G and H and the informed consent for the study (Exhibit 3) are submitted herewith for the Examiner's consideration.

A research study was initiated on April 20, 1999 in the United States in which patients were administered tablets of the formulation of Exhibit D, optionally in coadministration with digoxin. Copies of the formulation Exhibit D and the informed consent for the study (Exhibit 4) are submitted herewith for the Examiner's consideration.

A research study was initiated on August 27, 1999 in the United States in which patients were administered tablets of the formulation of Exhibit D optionally in coadministration with Gemfibrozil 600mg tablets. Copies of the formulation Exhibit D and the informed consent for the study (Exhibit 5) are submitted herewith for the Examiner's consideration.

In the Informed Consents accompanying the above research studies, Schering's active pharmaceutical ingredient, i.e., ezetimibe, was identified as "SCH 58235" and as an "experimental drug which inhibits the absorption of cholesterol". It was not identified by its chemical name, generic name or by its chemical formula.

It is our belief that these studies do not constitute prior public uses. Nevertheless, this information is being disclosed in accordance with 37 C.F.R. Section 1.56 out of an abundance of caution.

The Commissioner is authorized to charge Deposit Account No. 19-0365 for any additional fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington D.C., 20231 on 4/28/03

Ann Marie Cannoni

Registered Representative



Signature

4/28/03
Date

Respectfully submitted




Ann Marie Cannoni

Reg. No. 35,972

Attorney for Applicants

(908) 298-5024

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01490K

SERIAL NO.:

10/057,339**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*

APPLICANT:

T. Kosoglou, et al.

FILING DATE:

01/25/2002

GROUP:

1614**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

| | |
|----|--|
| AA | Exhibit A: SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary |
| AB | Exhibit B: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AC | Exhibit C: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AD | Exhibit D: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AE | Exhibit E: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AF | Exhibit F: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AG | Exhibit G: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AH | Exhibit H: SCH 58235 (ezetimibe), Drug Formulation Development Summary |
| AI | Exhibit 1: Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585 |
| AJ | Exhibit 2: Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112 |
| AK | Exhibit 3: Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566 |
| AL | Exhibit 4: Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130 |
| AM | Exhibit 5: Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8 |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAY 07 2003
TECH CENTER 1600/2900